Ratings by Clear Street (Kaveri Pohlman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/5/2026 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2026 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2026 | Rapt Therapeutics | RAPT | Downgrade | Hold (Buy) |
35.10 (58.02) |
65.3% | Details | |
| 1/20/2026 | Janux Therapeutics | JANX | Downgrade | Hold (Buy) |
13.76 (13.84) |
0.58% | Details | |
| 1/13/2026 | Oruka Therapeutics | ORKA | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2026 | Moonlake Immunotherapeutics | MLTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2026 | Ventyx Biosciences Inc | VTYX | Downgrade | Hold (Buy) |
10.05 (14.00) |
39.3% | Details | |
| 12/30/2025 | Palisade Bio Inc. | PALI | New Coverage | Buy (N/A) |
2.15 (1.63) |
-24.19% | Details | |
| 12/15/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2025 | Structure Therapeutics | GPCR | Maintain | Buy (N/A) |
|
Details | ||
| 12/5/2025 | Palvella Therapeutics | PVLA | New Coverage | Buy (N/A) |
91.91 (134.39) |
46.22% | Details | |
| 11/25/2025 | Jade Biosciences | JBIO | New Coverage | Buy (N/A) |
12.00 (14.05) |
17.08% | Details | |
| 11/14/2025 | Trevi Therapeutics | TRVI | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2025 | Zura Bio Ltd. | ZURA | New Coverage | Buy (N/A) |
4.42 (6.97) |
57.69% | Details | |
| 11/10/2025 | ArriVent BioPharma | AVBP | Maintain | Buy (N/A) |
|
Details | ||
| 11/7/2025 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 10/22/2025 | Sagimet Biosciences Inc | SGMT | New Coverage | Buy (N/A) |
7.83 (5.41) |
-30.91% | Details | |
| 10/7/2025 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 10/1/2025 | Ventyx Biosciences Inc | VTYX | New Coverage | Buy (N/A) |
3.03 (10.05) |
231.68% | Details | |
| 9/29/2025 | Rapt Therapeutics | RAPT | Maintain | Buy (N/A) |
|
Details | ||
| 9/29/2025 | Moonlake Immunotherapeutics | MLTX | Maintain | Buy (N/A) |
|
Details | ||
| 8/21/2025 | Oruka Therapeutics | ORKA | New Coverage | Buy (N/A) |
14.56 (32.97) |
126.44% | Details | |
| 8/7/2025 | Rapt Therapeutics | RAPT | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2025 | Moonlake Immunotherapeutics | MLTX | Maintain | Buy (N/A) |
|
Details | ||
| 7/30/2025 | Structure Therapeutics | GPCR | New Coverage | Buy (N/A) |
17.80 (57.73) |
224.33% | Details | |
| 7/9/2025 | Cargo Therapeutics | CRGX | Maintain | Hold (N/A) |
|
Details | ||
| 7/3/2025 | ArriVent BioPharma | AVBP | Maintain | Buy (Buy) |
|
Details | ||
| 7/3/2025 | Cullinan Oncology Inc. | CGEM | Maintain | Buy (Buy) |
|
Details | ||
| 6/25/2025 | ArriVent BioPharma | AVBP | New Coverage | Buy (N/A) |
22.80 (23.43) |
2.76% | Details | |
| 6/6/2025 | Rapt Therapeutics | RAPT | New Coverage | Buy (N/A) |
1.02 (35.10) |
3341.18% | Details | |
| 6/3/2025 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 4/30/2025 | Akero Therapeutics | AKRO | New Coverage | Buy (N/A) |
42.17 (54.74) |
29.81% | Details | |
| 3/6/2025 | Trevi Therapeutics | TRVI | Maintain | Buy (N/A) |
|
Details | ||
| 1/30/2025 | Madrigal Pharmaceuticals | MDGL | New Coverage | Buy (N/A) |
326.33 (432.83) |
32.64% | Details | |
| 12/12/2024 | Cargo Therapeutics | CRGX | New Coverage | Buy (N/A) |
16.40 (4.47) |
-72.74% | Details | |
| 12/12/2024 | Nuvation Bio Inc | NUVB | New Coverage | Buy (N/A) |
2.68 (4.59) |
71.27% | Details | |
| 12/12/2024 | Moonlake Immunotherapeutics | MLTX | New Coverage | Buy (N/A) |
53.54 (18.15) |
-66.1% | Details | |
| 12/12/2024 | Immatics | IMTX | New Coverage | Buy (N/A) |
7.52 (9.86) |
31.12% | Details | |
| 12/12/2024 | Cullinan Oncology Inc. | CGEM | New Coverage | Buy (N/A) |
12.52 (15.74) |
25.72% | Details | |
| 12/12/2024 | Janux Therapeutics | JANX | New Coverage | Buy (N/A) |
63.45 (13.76) |
-78.31% | Details | |
| 12/12/2024 | Erasca Inc | ERAS | New Coverage | Buy (N/A) |
2.78 (15.47) |
456.47% | Details | |
| 12/12/2024 | Protagonist Therapeutics | PTGX | New Coverage | Buy (N/A) |
41.00 (92.09) |
124.61% | Details | |
| 12/12/2024 | Enliven Therapeutics | ELVN | New Coverage | Buy (N/A) |
24.08 (29.44) |
22.26% | Details |
